GlassScriptPhysician profile
Nancy B Smith
NPI 1346405982
$5,220.32
in general payments reported to CMS, 2019-2025
41 companies · $810 in 2025
The $810 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,829 · 2022: $1,120 · 2023: $697 · 2024: $764 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $713.94 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $673.50 | 2021-2025 | |
| Lilly USA, LLC | $580.00 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $387.55 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $338.09 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $275.98 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $259.62 | 2022-2025 | Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $222.54 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $197.13 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.71 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $164.39 | 2021-2024 | Trintellix |
| Glaxosmithkline, LLC. | $107.63 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $86.52 | 2021-2022 | |
| Antares Pharma, INC. | $85.27 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Arbor Pharmaceuticals, INC. | $78.71 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.